Massachusetts-based AI-powered gene-editing company Arbor Biotechnologies has acquired gene-editing technology provider Serendipity Biosciences to enhance the development of novel gene-editing treatments and expand Arbor's genomic medicine portfolio. Financial details of the acquisitions were not disclosed.
Serendipity’s gene-editing assets, including genome editing based on RNA-guided endonuclease proteins Fanzor, IsrB, and other editing technologies, will help discover novel therapeutic applications for Arbor’s genomic medicine portfolio. Post-acquisition, Arbor Biotechnologies plans to leverage Serendipity's technologies to enhance and diversify its current nuclease technologies. This will reportedly allow potential therapeutic applications in reverse transcriptase (RT) editing and insertion of exons or entire genes in vivo.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.